Kenvue Shares Hit 20-Day High Amid Dividend Ruling
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 28 2026
0mins
Should l Buy KVUE?
Source: seekingalpha
Shares of Kenvue Inc. (KVUE.N) surged to a 20-day high today following a Texas judge's ruling that allows the company to proceed with a $398 million dividend payout. This decision comes despite ongoing litigation regarding the safety of Tylenol during pregnancy, which has been linked to autism claims. The judge determined she lacked jurisdiction over the dividend matter, emphasizing Kenvue's incorporation in Delaware and headquarters in New Jersey. While the ruling provides a temporary boost to investor confidence, the company still faces significant legal challenges, including a lawsuit from Texas Attorney General Ken Paxton that could have substantial financial implications if the appeals court allows the claims to proceed.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KVUE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KVUE
Wall Street analysts forecast KVUE stock price to rise
8 Analyst Rating
1 Buy
7 Hold
0 Sell
Hold
Current: 17.580
Low
17.00
Averages
18.86
High
23.00
Current: 17.580
Low
17.00
Averages
18.86
High
23.00
About KVUE
Kenvue Inc. is a consumer health company. The Company’s differentiated portfolio of brands includes Tylenol, Neutrogena, Listerine, Johnson’s, BAND-AID, Aveeno, Zyrtec, and Nicorette. It operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. Its Self Care product categories include pain care; cough, cold, and allergy; digestive health; smoking cessation; eye care; and other products. Self Care segments include brands such as Tylenol, Motrin, Nicorette, Benadryl, Zyrtec, Zarbee’s, ORSLTM, Rhinocort, and Calpol. The Skin Health and Beauty segment is focused on face and body care, as well as hair, sun, and other products. The Essential Health segment includes oral care, baby care, women’s health, wound care, and other products. Its portfolio includes Self Care, Skin Health and Beauty, and Essential Health products which connect with consumers across North America, Asia Pacific (APAC), Europe, Middle East, and Africa (EMEA), and Latin America (LATAM).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Growth Stocks Rebound, Dividend Investment Opportunities Emerge
- Dividend Investment Opportunity: As growth stocks rebound, investors can enter new dividend payers at relatively lower prices, particularly with PepsiCo's dividend yield rising to 3.7%, making it more attractive compared to Coca-Cola's 2.8%.
- PepsiCo Performance Recovery: Despite underperforming since 2023, PepsiCo's recent quarter saw a 2.6% organic revenue growth driven by innovation and price cuts, exceeding analysts' expectations and indicating potential for a rebound.
- Kenvue's Stable Returns: Kenvue, spun off from Johnson & Johnson, offers a 4.8% dividend yield despite slow revenue growth, appealing to investors seeking reliable cash flow, and is set to merge with Kimberly-Clark, enhancing its market position.
- Procter & Gamble's Consistent Growth: Procter & Gamble boasts a dividend yield of around 3% and has raised its annual per-share payout for 70 consecutive years, leveraging its strong brand and marketing capabilities to maintain a competitive edge in the consumer goods sector.
See More
Procter & Gamble Announces 70th Consecutive Dividend Increase
- Dividend Increase: Procter & Gamble raised its quarterly dividend from $1.0568 to $1.0885 per share, resulting in an annual payout of $4.354 and a forward yield of 3%, reflecting the company's ongoing commitment to shareholder returns.
- Dividend King Status: This increase positions P&G among only five companies that have raised dividends for over 70 consecutive years, further solidifying its status as a Dividend King and attracting income-focused investors.
- Market Competitiveness: As the largest household and personal products company globally, P&G demonstrates resilience with an operating margin exceeding 20%, despite facing consumer spending challenges, showcasing its ability to maintain stability during economic fluctuations.
- Investment Opportunity: The recent stock sell-off has pushed P&G's dividend yield to a five-year high, with a price-to-earnings ratio of 21.4 and a forward P/E of 20.8, presenting an attractive buying opportunity for value investors looking to anchor their passive income portfolios.
See More
Procter & Gamble Announces 70th Consecutive Dividend Increase
- Dividend Increase: Procter & Gamble raised its quarterly dividend from $1.0568 to $1.0885 per share, resulting in an annual payout of $4.354 and a forward yield of 3%, demonstrating the company's resilience amid economic slowdowns.
- Industry Position: As the largest household and personal products company globally, P&G ranks third in market capitalization among U.S. consumer staples, trailing only Walmart and Costco, highlighting its strong competitive edge in the market.
- Financial Health: With earnings per share at $6.75 and free cash flow at $6.09, P&G maintains a solid dividend payout ratio of 61.9%, indicating robust financial health while sustaining dividend growth.
- Market Adaptability: Despite consumer spending challenges, P&G effectively offsets weak performance in North America by leveraging a diversified product portfolio and geographic flexibility, ensuring continued growth in the global market.
See More
Kimberly-Clark's Dividend Yield Soars to 5.3%
- Dividend Growth History: Kimberly-Clark has raised its dividend for 54 consecutive years, making it one of 60 companies that have paid and increased dividends for at least 50 years, showcasing its strong cash flow stability and long-term investor confidence.
- Yield Surge: The company's dividend yield has soared to 5.3% due to falling stock prices, and despite facing pressure on sales growth and profit margins, its operating cash flow remains sufficient to support dividends and share repurchase plans.
- Market Environment Challenges: Kimberly-Clark's stock is hovering around a 12-year low, impacted by inflation, weak consumer spending, and uncertainty surrounding the Kenvue acquisition, which has dampened investor sentiment in the short term.
- Long-Term Investment Opportunity: Despite short-term challenges, Kimberly-Clark's strong brands like Huggies and Kleenex maintain significant market positions, providing long-term investors with an opportunity to acquire shares at discounted prices.
See More
Kimberly-Clark Maintains Dividend Amid Earnings Decline
- Dividend Support Capability: Despite falling earnings, Kimberly-Clark can still support its dividend payments through operational cash flow, demonstrating financial resilience, especially as many high-yield stocks rely on debt.
- Acquisition Progress: Kimberly-Clark is expected to close its acquisition of Kenvue in the second half of 2026, a strategic move that will enhance its product portfolio and strengthen market competitiveness.
- Attracting Value Investors: With a dividend yield soaring to 5.3%, Kimberly-Clark stands out as an appealing option for income-focused investors, particularly as the S&P 500's dividend yield has dropped to 1.2%.
- Long-Term Growth Potential: Despite pressures from rising costs and weak consumer spending, Kimberly-Clark anticipates accelerating organic growth by the second half of 2026, with management aiming for at least 40% gross margins by the end of the decade, showcasing strong long-term growth potential.
See More
Strong Performance Fuels Promising Growth Outlook
- Significant Revenue Growth: Johnson & Johnson reported a 9.9% year-over-year revenue increase in Q1, reaching $24.06 billion, surpassing the market expectation of $23.63 billion, which underscores the company's robust performance in pharmaceuticals and medical technology, further solidifying its market position.
- Adjusted EPS Exceeds Expectations: The adjusted earnings per share for the first quarter stood at $2.70, exceeding the anticipated $2.66, reflecting effective management in cost control and profitability, which enhances investor confidence.
- Strong New Drug Sales: Sales of the blood cancer therapy Darzalex rose 22.5% year-over-year to $3.96 billion, exceeding market expectations, while Tremfya sales surged 68% to $1.61 billion, showcasing Johnson & Johnson's competitiveness and market demand in innovative pharmaceuticals.
- Optimistic Future Growth Guidance: Johnson & Johnson raised its full-year guidance, projecting revenue growth between 5.9% and 6.9%, with adjusted EPS expectations increased to a range of $11.45 to $11.65, indicating the company's confidence in future performance and positive market outlook.
See More
Growth Stocks Rebound, Dividend Investment Opportunities Emerge
- Dividend Investment Opportunity: As growth stocks rebound, investors can enter new dividend payers at relatively lower prices, particularly with PepsiCo's dividend yield rising to 3.7%, making it more attractive compared to Coca-Cola's 2.8%.
- PepsiCo Performance Recovery: Despite underperforming since 2023, PepsiCo's recent quarter saw a 2.6% organic revenue growth driven by innovation and price cuts, exceeding analysts' expectations and indicating potential for a rebound.
- Kenvue's Stable Returns: Kenvue, spun off from Johnson & Johnson, offers a 4.8% dividend yield despite slow revenue growth, appealing to investors seeking reliable cash flow, and is set to merge with Kimberly-Clark, enhancing its market position.
- Procter & Gamble's Consistent Growth: Procter & Gamble boasts a dividend yield of around 3% and has raised its annual per-share payout for 70 consecutive years, leveraging its strong brand and marketing capabilities to maintain a competitive edge in the consumer goods sector.
See More
Procter & Gamble Announces 70th Consecutive Dividend Increase
- Dividend Increase: Procter & Gamble raised its quarterly dividend from $1.0568 to $1.0885 per share, resulting in an annual payout of $4.354 and a forward yield of 3%, reflecting the company's ongoing commitment to shareholder returns.
- Dividend King Status: This increase positions P&G among only five companies that have raised dividends for over 70 consecutive years, further solidifying its status as a Dividend King and attracting income-focused investors.
- Market Competitiveness: As the largest household and personal products company globally, P&G demonstrates resilience with an operating margin exceeding 20%, despite facing consumer spending challenges, showcasing its ability to maintain stability during economic fluctuations.
- Investment Opportunity: The recent stock sell-off has pushed P&G's dividend yield to a five-year high, with a price-to-earnings ratio of 21.4 and a forward P/E of 20.8, presenting an attractive buying opportunity for value investors looking to anchor their passive income portfolios.
See More
Procter & Gamble Announces 70th Consecutive Dividend Increase
- Dividend Increase: Procter & Gamble raised its quarterly dividend from $1.0568 to $1.0885 per share, resulting in an annual payout of $4.354 and a forward yield of 3%, demonstrating the company's resilience amid economic slowdowns.
- Industry Position: As the largest household and personal products company globally, P&G ranks third in market capitalization among U.S. consumer staples, trailing only Walmart and Costco, highlighting its strong competitive edge in the market.
- Financial Health: With earnings per share at $6.75 and free cash flow at $6.09, P&G maintains a solid dividend payout ratio of 61.9%, indicating robust financial health while sustaining dividend growth.
- Market Adaptability: Despite consumer spending challenges, P&G effectively offsets weak performance in North America by leveraging a diversified product portfolio and geographic flexibility, ensuring continued growth in the global market.
See More
Kimberly-Clark's Dividend Yield Soars to 5.3%
- Dividend Growth History: Kimberly-Clark has raised its dividend for 54 consecutive years, making it one of 60 companies that have paid and increased dividends for at least 50 years, showcasing its strong cash flow stability and long-term investor confidence.
- Yield Surge: The company's dividend yield has soared to 5.3% due to falling stock prices, and despite facing pressure on sales growth and profit margins, its operating cash flow remains sufficient to support dividends and share repurchase plans.
- Market Environment Challenges: Kimberly-Clark's stock is hovering around a 12-year low, impacted by inflation, weak consumer spending, and uncertainty surrounding the Kenvue acquisition, which has dampened investor sentiment in the short term.
- Long-Term Investment Opportunity: Despite short-term challenges, Kimberly-Clark's strong brands like Huggies and Kleenex maintain significant market positions, providing long-term investors with an opportunity to acquire shares at discounted prices.
See More
Kimberly-Clark Maintains Dividend Amid Earnings Decline
- Dividend Support Capability: Despite falling earnings, Kimberly-Clark can still support its dividend payments through operational cash flow, demonstrating financial resilience, especially as many high-yield stocks rely on debt.
- Acquisition Progress: Kimberly-Clark is expected to close its acquisition of Kenvue in the second half of 2026, a strategic move that will enhance its product portfolio and strengthen market competitiveness.
- Attracting Value Investors: With a dividend yield soaring to 5.3%, Kimberly-Clark stands out as an appealing option for income-focused investors, particularly as the S&P 500's dividend yield has dropped to 1.2%.
- Long-Term Growth Potential: Despite pressures from rising costs and weak consumer spending, Kimberly-Clark anticipates accelerating organic growth by the second half of 2026, with management aiming for at least 40% gross margins by the end of the decade, showcasing strong long-term growth potential.
See More
Strong Performance Fuels Promising Growth Outlook
- Significant Revenue Growth: Johnson & Johnson reported a 9.9% year-over-year revenue increase in Q1, reaching $24.06 billion, surpassing the market expectation of $23.63 billion, which underscores the company's robust performance in pharmaceuticals and medical technology, further solidifying its market position.
- Adjusted EPS Exceeds Expectations: The adjusted earnings per share for the first quarter stood at $2.70, exceeding the anticipated $2.66, reflecting effective management in cost control and profitability, which enhances investor confidence.
- Strong New Drug Sales: Sales of the blood cancer therapy Darzalex rose 22.5% year-over-year to $3.96 billion, exceeding market expectations, while Tremfya sales surged 68% to $1.61 billion, showcasing Johnson & Johnson's competitiveness and market demand in innovative pharmaceuticals.
- Optimistic Future Growth Guidance: Johnson & Johnson raised its full-year guidance, projecting revenue growth between 5.9% and 6.9%, with adjusted EPS expectations increased to a range of $11.45 to $11.65, indicating the company's confidence in future performance and positive market outlook.
See More
